Breast Cancer News and Research

Latest Breast Cancer News and Research

Imaging Diagnostic Systems to showcase CT Laser Breast imaging system at FIME 2011

Imaging Diagnostic Systems, Inc., a pioneer in optical breast imaging announced today that it will be exhibiting its CT Laser Breast imaging (CTLM) system at the FIME 2011 conference August 10-12, 2011 in Miami Beach, Florida. IDSI's Head of Clinical Research, Dr Jose Cineros will be a feature speaker at the exhibition.

4 Aug 2011

Innovative delivery systems and methods to treat breast cancer

In their lifetime, women have more than a 12 percent risk of being diagnosed with breast cancer. 1 This week, research on novel approaches to breast cancer treatment is being presented at the Era of Hope (EOH) conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program (BCRP).

4 Aug 2011

Conference to discuss novel studies that address how inherited genes cause breast cancer

A woman's ethnicity as well as her genetic makeup are two of the main risk factors for hereditary breast cancer. Research into understanding and treating hereditary breast cancer will be presented today at the Era of Hope conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program.

4 Aug 2011

Fatty acids, nutrients during pregnancy can reduce risk of breast cancer in female offspring

Era of Hope conference to feature compelling research examining benefits to daughters During pregnancy, women are counseled to refrain from consuming certain types of foods, beverages and medications in order to avoid jeopardizing the health and development of the fetus.

4 Aug 2011

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.

4 Aug 2011

Celldex second quarter net loss increases to $10.2 million

Celldex Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2011. Celldex reported a net loss of $10.2 million, or $0.27 per share, for the second quarter of 2011 compared to a net loss of $9.5 million, or $0.30 per share, for the second quarter of 2010.

3 Aug 2011

Federal appeals court partially reverses ruling in BRCA patents case

In a 2-1 decision, a federal appeals court today partially reversed a lower court's ruling in a case challenging patents on two human genes, BRCA1 and BRCA2, associated with hereditary breast and ovarian cancer. The court ruled that companies can obtain patents on the genes but cannot patent methods to compare those gene sequences.

3 Aug 2011

A guide to safe and informed recovery after prostate cancer

Prostate cancer is the number two killer of American men, second only to lung cancer. It is a disease that affects more than 2 million American men, and in 2010 there were over 218,000 new diagnoses.

2 Aug 2011

PSI develops new breast cancer diagnostic method

The Paul Scherrer Institute (PSI) has developed a new breast cancer diagnostic method, and is now carrying out first tests on non-preserved human tissue in conjunction with the Kantonsspital Baden AG. This new method should be able to reveal structures that cannot be seen using conventional mammography. Standard procedures only determine the extent to which X-rays are attenuated by various tissue structures.

2 Aug 2011

Taxoxifen combined with dasatinib reverses chemo-resistance in breast cancer cells

Taking a leukemia chemotherapy drug may help breast cancer patients who don't respond to tamoxifen overcome resistance to the widely-used drug, new research from the Kimmel Cancer Center at Jefferson suggests.

2 Aug 2011

Disparities persist despite insurance

A pair of studies highlights how health disparities continue to take shape and unravels some of the factors that are involved in differences in health outcomes.

1 Aug 2011

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed its Phase I study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

1 Aug 2011

One in four British women at risk of cancer

A cancer charity revealed figures that show that British women are nearly a fifth more likely to develop cancer at some point during their lives than their European counterparts. Most of it is blamed on lifestyle factors such as obesity and alcohol consumption.

31 Jul 2011

Human genes can be patented in U.S. - Court overrules previous ruling

A lower court in the U.S. had earlier ruled that human genes cannot be patented by biotech companies who use them for diagnostic purposes. Now a federal appeals court ruled on Friday that genes can be patented. The Court of Appeals for the Federal Circuit, which specializes in patent cases, said that Myriad Genetics was entitled to patents on two human genes used to predict if women have an increased risk of getting breast and ovarian cancer.

31 Jul 2011

UT Southwestern's support group book shares stories of members whose wives battled cancer

When a loved one has cancer, it affects the entire family. For men, many of whom are less likely to take advantage of a support group, this can leave a void with devastating emotional consequences.

30 Jul 2011

UCSD researchers examine association of energy balance, breast cancer

A team of researchers from the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center will be participating in a cooperative agreement initiative, funded by the National Cancer Institute of the National Institutes of Health, with four other major cancer centers.

30 Jul 2011

EGT transfers clinical grade lentiviral vector to MSKCC

Errant Gene Therapeutics, LLC, a pioneering boutique drug development firm specializing in Rare Diseases, announced the transfer of its clinical grade lentiviral vector, TNS 9.55.3, to Memorial Sloan Kettering Cancer Center.

29 Jul 2011

'Systems biology' study of breast cancer

Using a "systems biology" approach - which focuses on understanding the complex relationships between biological systems - to look under the hood of an aggressive form of breast cancer, researchers for the first time have identified a set of proteins in the blood that change in abundance long before the cancer is clinically detectable.

29 Jul 2011

Houston-based Mattress Firm commits to support pancreatic cancer research

Mattress Firm, a leading specialty mattress retailer with more than 720 stores nationwide, is committed to supporting the fight against pancreatic cancer by raising funds for clinical trials through the Translational Genomics Research Institute (TGen) globalCure initiative.

29 Jul 2011

Introducing maspin protein into tumor nucleus can stop growth and spread of cancer

According to the Canadian Cancer Society, one in four Canadians will die of cancer. This year alone, the disease will kill an estimated 75,000 people. With incidence rates on the rise, more cancer patients are facing grave prognoses.

29 Jul 2011